UA97660C2 - Жидкие композиции солей 4-[2-(4-метилфенилсульфанил)фенил]-пиперидина - Google Patents

Жидкие композиции солей 4-[2-(4-метилфенилсульфанил)фенил]-пиперидина

Info

Publication number
UA97660C2
UA97660C2 UAA200910359A UAA200910359A UA97660C2 UA 97660 C2 UA97660 C2 UA 97660C2 UA A200910359 A UAA200910359 A UA A200910359A UA A200910359 A UAA200910359 A UA A200910359A UA 97660 C2 UA97660 C2 UA 97660C2
Authority
UA
Ukraine
Prior art keywords
piperidine
phenyl
salts
liquid formulations
methylphenylsulfanyl
Prior art date
Application number
UAA200910359A
Other languages
English (en)
Ukrainian (uk)
Inventor
Гудрун Ласкогэн
Тине Брайан Стенсбьол
де Дуего Хэйди Лопэс
Original Assignee
Х. Луннбэк А/С
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Х. Луннбэк А/С filed Critical Х. Луннбэк А/С
Priority claimed from PCT/DK2008/050062 external-priority patent/WO2008113358A1/en
Publication of UA97660C2 publication Critical patent/UA97660C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4465—Non condensed piperidines, e.g. piperocaine only substituted in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Изобретение касается жидких композиций солей DL-молочной кислоты, глутаровой кислоты, L-аспарагиновой кислоты и глутаминовой кислоты с 4-[2-(4-метилфенилсульфанил)фенил]пиперидином и их применения в изготовлении лекарственного средства, используемого в лечении заболеваний ЦНС.
UAA200910359A 2007-03-20 2008-03-14 Жидкие композиции солей 4-[2-(4-метилфенилсульфанил)фенил]-пиперидина UA97660C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200700423 2007-03-20
PCT/DK2008/050062 WO2008113358A1 (en) 2007-03-20 2008-03-14 Liquid formulations of salts of 4-[2-(4-methylphenylsulfanyl)phenyl]piperidine

Publications (1)

Publication Number Publication Date
UA97660C2 true UA97660C2 (ru) 2012-03-12

Family

ID=39575680

Family Applications (2)

Application Number Title Priority Date Filing Date
UAA200910359A UA97660C2 (ru) 2007-03-20 2008-03-14 Жидкие композиции солей 4-[2-(4-метилфенилсульфанил)фенил]-пиперидина
UAA200910338A UA99611C2 (ru) 2007-03-20 2008-03-14 Способ лечения дефицита внимания с гиперактивностью (adhd) и применение 4-[2-(4-метилфенилсульфанил)фенил]пиперидина для производства лекарственного средства

Family Applications After (1)

Application Number Title Priority Date Filing Date
UAA200910338A UA99611C2 (ru) 2007-03-20 2008-03-14 Способ лечения дефицита внимания с гиперактивностью (adhd) и применение 4-[2-(4-метилфенилсульфанил)фенил]пиперидина для производства лекарственного средства

Country Status (28)

Country Link
US (2) US20100144788A1 (ru)
EP (2) EP2139479B1 (ru)
JP (1) JP5388867B2 (ru)
KR (1) KR20090125775A (ru)
CN (2) CN101674830B (ru)
AR (1) AR065798A1 (ru)
AU (1) AU2008228639B2 (ru)
BR (1) BRPI0808831A2 (ru)
CA (1) CA2684556C (ru)
CL (1) CL2008000796A1 (ru)
CO (1) CO6220957A2 (ru)
CY (2) CY1113965T1 (ru)
DK (2) DK2139479T3 (ru)
EA (1) EA017407B1 (ru)
ES (2) ES2399305T3 (ru)
HK (1) HK1142007A1 (ru)
HR (1) HRP20130049T1 (ru)
IL (1) IL200954A (ru)
MX (1) MX2009009934A (ru)
MY (1) MY163537A (ru)
NZ (1) NZ579723A (ru)
PL (2) PL2139479T3 (ru)
PT (2) PT2139479E (ru)
RS (2) RS52676B (ru)
SI (1) SI2139479T1 (ru)
TW (1) TWI432194B (ru)
UA (2) UA97660C2 (ru)
WO (1) WO2008113360A2 (ru)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2656057C (en) * 2006-06-16 2012-10-02 H. Lundbeck A/S Crystalline forms of 4-[2-(4-methylphenylsulfanyl)-phenyl]piperidine with combined serotonin and norepinephrine reuptake inhibition for the treatment of neuropathic pain
TWI432194B (zh) 2007-03-20 2014-04-01 Lundbeck & Co As H ４-〔２-（４-甲基苯硫基）苯基〕哌啶之新穎治療用途
JP5764327B2 (ja) * 2007-06-15 2015-08-19 ハー・ルンドベック・アクチエゼルスカベット 過敏性腸症候群（ｉｂｓ）を処置するための４−［２−（４−メチルフェニルスルファニル）フェニル］ピペリジン
TW200938194A (en) * 2007-12-14 2009-09-16 Lundbeck & Co As H Therapeutic uses of compounds having affinity to the serotonin transporter, serotonin receptors and noradrenalin transporter
WO2011136373A1 (ja) * 2010-04-30 2011-11-03 武田薬品工業株式会社 腸溶性錠剤
US9311462B1 (en) 2011-03-04 2016-04-12 Zynga Inc. Cross platform social networking authentication system
US8332488B1 (en) 2011-03-04 2012-12-11 Zynga Inc. Multi-level cache with synch
US8347322B1 (en) 2011-03-31 2013-01-01 Zynga Inc. Social network application programming interface
US10135776B1 (en) 2011-03-31 2018-11-20 Zynga Inc. Cross platform social networking messaging system
US8522137B1 (en) 2011-06-30 2013-08-27 Zynga Inc. Systems, methods, and machine readable media for social network application development using a custom markup language
JP2019524682A (ja) 2016-07-01 2019-09-05 ハー・ルンドベック・アクチエゼルスカベット 抗うつ作用の速い発現のためのボルチオキセチン投与計画

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002516282A (ja) * 1998-05-22 2002-06-04 イーライ・リリー・アンド・カンパニー 難治性鬱病の処置のための組合せ治療
UA81749C2 (ru) * 2001-10-04 2008-02-11 Х. Луннбек А/С производные фенилпиперазина как ингибиторы обратного захвата серотонинА
ATE406894T1 (de) * 2003-04-04 2008-09-15 Lundbeck & Co As H 4-(2-phenylsulfanyl-phenyl)-piperidin-derivate als serotonin-wiederaufnahme-hemmer
EP1635828B1 (en) * 2003-04-04 2008-04-23 H. Lundbeck A/S 4-(2-phenyloxyphenyl)-piperidine or -1,2,3,6-tetrahydropyridine derivatives as serotonin reuptake inhibitors
AR052308A1 (es) * 2004-07-16 2007-03-14 Lundbeck & Co As H Derivados de 2-(1h-indolilsulfanil)-arilamina y una composicion farmaceutica que contiene al compuesto
DE102006028034A1 (de) * 2006-06-14 2007-12-20 Leifheit Ag Bürste und Kehrgerät mit Bürste
CA2656057C (en) * 2006-06-16 2012-10-02 H. Lundbeck A/S Crystalline forms of 4-[2-(4-methylphenylsulfanyl)-phenyl]piperidine with combined serotonin and norepinephrine reuptake inhibition for the treatment of neuropathic pain
TWI432194B (zh) 2007-03-20 2014-04-01 Lundbeck & Co As H ４-〔２-（４-甲基苯硫基）苯基〕哌啶之新穎治療用途
TWI405588B (zh) 2007-03-20 2013-08-21 Lundbeck & Co As H ４-〔２-（４-甲苯基硫基）-苯基〕哌啶之鹽類的液體調配物
TW200938194A (en) * 2007-12-14 2009-09-16 Lundbeck & Co As H Therapeutic uses of compounds having affinity to the serotonin transporter, serotonin receptors and noradrenalin transporter

Also Published As

Publication number Publication date
MY163537A (en) 2017-09-15
NZ579723A (en) 2011-07-29
AU2008228639B2 (en) 2012-12-13
CY1113965T1 (el) 2016-07-27
CO6220957A2 (es) 2010-11-19
KR20090125775A (ko) 2009-12-07
EP2167085A1 (en) 2010-03-31
ES2445400T3 (es) 2014-03-03
WO2008113360A2 (en) 2008-09-25
UA99611C2 (ru) 2012-09-10
CY1114774T1 (el) 2016-12-14
EP2139479B1 (en) 2012-12-12
EA017407B1 (ru) 2012-12-28
MX2009009934A (es) 2009-09-24
PT2139479E (pt) 2013-02-20
SI2139479T1 (sl) 2013-04-30
PT2167085E (pt) 2014-02-17
US8507526B2 (en) 2013-08-13
CN101674830A (zh) 2010-03-17
CN101646438A (zh) 2010-02-10
BRPI0808831A2 (pt) 2014-08-26
JP5388867B2 (ja) 2014-01-15
IL200954A (en) 2014-12-31
DK2139479T3 (da) 2013-02-11
PL2167085T3 (pl) 2014-08-29
US20100137366A1 (en) 2010-06-03
TWI432194B (zh) 2014-04-01
HRP20130049T1 (hr) 2013-02-28
CN101646438B (zh) 2012-04-11
CA2684556A1 (en) 2008-09-25
DK2167085T3 (da) 2014-02-03
IL200954A0 (en) 2010-05-17
JP2010521502A (ja) 2010-06-24
HK1142007A1 (en) 2010-11-26
EP2139479A2 (en) 2010-01-06
US20100144788A1 (en) 2010-06-10
AR065798A1 (es) 2009-07-01
TW200848032A (en) 2008-12-16
WO2008113360A3 (en) 2008-11-13
EA200970871A1 (ru) 2010-04-30
EP2167085B1 (en) 2013-12-25
RS53138B (en) 2014-06-30
PL2139479T3 (pl) 2013-05-31
RS52676B (en) 2013-06-28
ES2399305T3 (es) 2013-03-27
CL2008000796A1 (es) 2008-09-26
CN101674830B (zh) 2012-05-09
AU2008228639A1 (en) 2008-09-25
CA2684556C (en) 2013-01-08

Similar Documents

Publication Publication Date Title
UA97660C2 (ru) Жидкие композиции солей 4-[2-(4-метилфенилсульфанил)фенил]-пиперидина
NZ601483A (en) Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
EA201290116A1 (ru) Новые композиции 1-[2-(2,4-диметилфенилсульфанил)фенил]пиперазина
EA201100358A1 (ru) Дабигатран для чрескожной хирургической катетеризации сердца
MY155517A (en) Heterocyclic derivatives
IN2012DN03337A (ru)
IL237820A (en) Using a History of 4- (1-Carboxy-Ethylcarbamoyl) -4- (5- [2,1] Ditheolan-3-Il-Pentanoylamino) - Butyric Acid for Drug Preparation
IN2012DN01233A (ru)
MY138941A (en) Aryl-pyridine derivatives
MY143568A (en) 11b-hsd1 inhibitors for the treatment of diabetes
MX2010008583A (es) Novedosos formas cristalinas de acido 4-[4-(2-adamantilcarbamoil)- 5-ter-butil-pirazol-1-il]benzoico.
BR112012018386A2 (pt) "inibidores isoindolinona de fosfatidilinositol 3-quinase"
ATE552002T1 (de) Feste zubereitung zur oralen verabreichung
TW200716628A (en) Novel compounds
NZ601121A (en) 5-alkynyl-pyrimidines
MY166789A (en) Arginine salts and their uses for the treatment of illnesses in the oral cavity
NZ619076A (en) Isoxazolines as inhibitors of fatty acid amide hydrolase
MX2010005824A (es) Derivados de aminotiazol.
TW200616958A (en) New alkyl-pyridines as 11-beta inhibitors for diabetes
EA201171287A1 (ru) Жидкие составы солей 1-[2-(2,4-диметилфенилсульфанил)фенил]пиперазина
MX2010002341A (es) Derivados de bencimidazol usados como agonistas del receptor x de farnesoide.
MX2009011749A (es) Compuestos triciclicos como inhibidores de metaloproteinasa matricial.
DK1749517T3 (da) Stabil farmaceutiske sammensætning af linezolid form IV
MX2012007582A (es) Compuestos de 4-fenoxi-nicotinamida o 4-fenoxi-pirimidina-5-carbox amida.
GEP20166488B (en) Co-crystals and salts of ccr3-inhibitors